AVAMYS 27.5 MCG — DIN 02298589
FLUTICASONE FUROATE : 27.5 MCG · GLAXOSMITHKLINE INC · SPRAY, METERED DOSE · wholesale supply in Canada
Health Canada status: MARKETED
What is AVAMYS?
AVAMYS 27.5 MCG contains FLUTICASONE FUROATE : 27.5 MCG. It is listed in the Health Canada Drug Product Database under DIN 02298589, held by GLAXOSMITHKLINE INC, supplied as SPRAY, METERED DOSE for NASAL administration. Health Canada currently lists it as marketed, status dated 22-Oct-2007. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AVAMYS used for?
AVAMYS (fluticasone furoate nasal spray) is indicated for the treatment of the symptoms of seasonal and perennial allergic rhinitis in patients 2 years of age and older. Seasonal allergic rhinitis: also called “hay fever"; Perennial allergic rhinitis: year round allergies.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Fluticasone Furoate cost around the world?
Fluticasone Furoate is listed on 4 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Greece publishes a producer price (ex-factory); Italy publishes a prezzo al pubblico (classe A); Morocco publishes a PPV (public price). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| Greece | producer price (ex-factory) | 26 | 26 |
| Italy | prezzo al pubblico (classe A) | 20 | 20 |
| Morocco | PPV (public price) | 7 | 20 |
| United Kingdom | hospital | 1 | 1 |
67 pack listings across 54 brand entries and 4 price bases, refreshed 05 Sep 2026. Ranges span every Fluticasone Furoate pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 27.5 MCG |
|---|---|
| Dosage form | SPRAY, METERED DOSE |
| Route | NASAL |
| Pack configuration (monograph) | AVAMYS 27.5 mcg is supplied in an amber glass bottle enclosed in a nasal device with a small, short nozzle and a side-actuated mist-release button to actuate the spray. Each bottle contains a net fill weight of 4.5 g or 10 g and will provide 30 or 120 metered sprays, respectively, after the initial priming. The nasal device should be discarded after the labelled amount of sprays has been used. |
| Storage | Store the device between 4 and 30°C, in the upright position with the cap in place. Do not refrigerate or freeze. Keep out of reach and sight of children. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Fluticasone Furoate |
|---|---|
| ATC code | R01AD12 |
| AHFS class | 52:08.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02298589 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2298589 |
| Brand name | AVAMYS |
| Generic / active ingredient | FLUTICASONE FUROATE : 27.5 MCG |
| Market authorization holder | GLAXOSMITHKLINE INC |
| Health Canada schedule | Prescription |
| ATC code | R01AD12 |
| ATC anatomical main group | R — Respiratory system |
| ATC therapeutic subgroup | R01AD |
| Current status | MARKETED |
| Status date | 22-Oct-2007 |
| Original market date | 2007-10-22 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults and adolescents 12 years of age and older: The recommended dosage is two sprays (27.5 mcg of fluticasone furoate per spray) in each nostril once daily (total daily dose, 110 mcg). Pediatrics (2 to < 12 years of age): The recommended starting dosage is one spray (27.5 mcg of fluticasone furoate per spray) in each nostril once daily (total daily dose, 55 mcg). Patients not adequately responding to one spray in each nostril once daily (total daily dose, 55 mcg) may use two sprays in each nostril once daily (total daily dose, 110 mcg). Once adequate control of symptoms is achieved, dose reduction to one spray in each nostril once daily (total daily dose, 55 mcg) is recommended. For full therapeutic benefit, regular scheduled usage is recommended. Onset of action has been observed as early as 8 hours after initial administration in Seasonal Allergic Rhinitis (SAR) and as early as 24 hours after initial administration in Perennial Allergic Rhinitis (PAR). It may take several days of treatment to achieve maximum benefit. An absence of an immediate effect should be explained to the patient. Similarly, when corticosteroids are discontinued, symptoms may not return for several days. AVAMYS should be administered only by the intranasal route. It is necessary to prime the pump with 6 actuations before first use or after 30 days of non-use or if the cap has been left off for more than 5 days. AVAMYS may be administered at any time of day. Illustrated instructions for proper use appear in PATIENT MEDICATION INFORMATION. Missed Dose: If a single dose is missed, instruct the patient to take the next dose when it is due. Do not instruct the patient to take an extra dose.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
AVAMYS is contraindicated in patients with a hypersensitivity to any of its ingredients.
Warnings and precautions
Ear/Nose/Throat: Epistaxis and Nasal Ulceration, Candida albicans infection, Impaired wound healing, Nasal Septal Perforation. Endocrine and Metabolism: Hypercorticism and Adrenal Suppression, Effects on Growth. Hepatic/Biliary/Pancreatic: Fluticasone furoate undergoes extensive first-pass metabolism by the liver enzyme CYP3A4, therefore the pharmacokinetics of AVAMYS in patients with moderate and severe liver disease may be altered. Based on data with another glucocorticoid metabolized by CYP3A4, coadministration with ritonavir is not recommended because of the risk of systemic effects secondary to increased exposure to fluticasone furoate. Immune: As with all medications containing a corticosteroid, AVAMYS should be administered with caution, and only if necessary, in patients with active or quiescent tuberculosis infections of the respiratory tract; chronic or untreated infections such as systemic fungal, bacterial, viral, or parasitic; or ocular herpes simplex. Corticosteroids may mask some signs of infection and new infections may appear. A decreased resistance to localized infections has been observed during corticosteroid therapy; this may require treatment with appropriate therapy or stopping the administration of AVAMYS nasal spray. Ophthalmologic: Nasal and inhaled corticosteroids may result in the development of glaucoma, cataracts and/or central serous chorioretinopathy (CSCR). Therefore, close monitoring is warranted in patients with a change in vision or with a history of increased intraocular pressure (IOP), glaucoma, cataracts, and/or CSCR.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
2 · Same class — other molecules in ATC R01AD
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Mometasone | APO-MOMETASONE · MOMETASONE · MOSASPRAY · NASAL ALLERGY AND CONGESTION RELIEF · +4 more | 9 | 6 | Yes |
| Fluticasone | 24HR NASAL ALLERGY RELIEF · ALLERGY RELIEF NASAL SPRAY · APO-FLUTICASONE · FLONASE - AEM-SUS NAS 50MCG/MD · +5 more | 9 | 4 | Yes |
| Budesonide | MYLAN-BUDESONIDE AQ · RHINOCORT AQUA · RHINOCORT AQUA 100MCG · RHINOCORT TURBUHALER 100 MCG/DOSE | 5 | 3 | Yes |
| Triamcinolone | APO-TRIAMCINOLONE AQ · NASACORT · NASACORT ALLERGY 24HR · NASACORT AQ · +1 more | 5 | 3 | Yes |
| Fluticasone, Combinations | APO-AZELASTINE/FLUTICASONE · DYMISTA · MYLAN-AZELASTINE/FLUTICASONE | 3 | 3 | Yes |
| Beclomethasone | APO-BECLOMETHASONE NASAL SPRAY · BECLOMETHASONE AQUEOUS NASAL SPRAY 50MCG/METERED DOSE · BECLOMETHASONE DIPROPIONATE NAS-SPR 50MCG/AEM · BECLOMETHASONE DIPROPIONATE NASAL INHALER · +8 more | 13 | 2 | Yes |
| Ciclesonide | APO-CICLESONIDE · OMNARIS · OMNARIS HFA | 3 | 1 | Yes |
| Fluticasone Furoate | AVAMYS | 1 | 1 | Yes |
| Mometasone, Combinations | RYALTRIS | 1 | 1 | Yes |
| Flunisolide | APO-FLUNISOLIDE NASAL SPRAY · NOVO-FLUNISOLIDE · PMS-FLUNISOLIDE · RATIO-FLUNISOLIDE · +2 more | 6 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC R01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| R01AA | Ephedrine · Oxymetazoline · Phenylephrine · Xylometazoline | 76 | 18 |
| R01AX | Combinations · Ipratropium Bromide · Various | 42 | 4 |
| R01AB | Ephedrine · Naphazoline · Oxymetazoline · Phenylephrine | 12 | 1 |
| R01AC | Cromoglicic Acid · Levocabastine | 6 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is AVAMYS called?
Also recorded in Canada as: 14 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler [Breo] (US), 30 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler [Breo] (US), 30 ACTUAT fluticasone furoate 0.1 MG/ACTUAT Dry Powder Inhaler [Arnuity] (US), 14 ACTUAT fluticasone furoate 0.1 MG/ACTUAT Dry Powder Inhaler [Arnuity] (US), 14 ACTUAT fluticasone furoate 0.2 MG/ACTUAT Dry Powder Inhaler [Arnuity] (US), 30 ACTUAT fluticasone furoate 0.2 MG/ACTUAT Dry Powder Inhaler [Arnuity] (US), 14 ACTUAT fluticasone furoate 0.2 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler [Breo] (US), 30 ACTUAT fluticasone furoate 0.2 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler [Breo] (US), fluticasone furoate 0.0275 MG/ACTUAT Metered Dose Nasal Spray [Flonase Sensimist] (US), 30 ACTUAT fluticasone furoate 0.05 MG/ACTUAT Dry Powder Inhaler [Arnuity] (US), 30 ACTUAT fluticasone furoate 0.05 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler [Breo] (US), 30 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler (US), 14 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler (US), 30 ACTUAT fluticasone furoate 0.1 MG/ACTUAT Dry Powder Inhaler (US), 14 ACTUAT fluticasone furoate 0.1 MG/ACTUAT Dry Powder Inhaler (US).
The same molecule, Fluticasone Furoate, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| FLIXOTIDE DISKUS | Latin | Morocco |
| CUTIVATE | Latin | Morocco |
| FLIXOTIDE | Latin | Morocco |
| FLOTEC | Latin | Morocco |
| FLIXONASE | Latin | Morocco |
| FLUZAIR | Latin | Morocco |
| NAZAIR | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.